Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.

Saba K, Wettstein MS, Lieger L, Hötker AM, Donati OF, Moch H, Ankerst DP, Poyet C, Sulser T, Eberli D, Mortezavi A.

J Urol. 2019 Oct 25:101097JU0000000000000622. doi: 10.1097/JU.0000000000000622. [Epub ahead of print]

PMID:
31651228
2.

Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools.

Tolksdorf J, Kattan MW, Boorjian SA, Freedland SJ, Saba K, Poyet C, Guerrios L, De Hoedt A, Liss MA, Leach RJ, Hernandez J, Vertosick E, Vickers AJ, Ankerst DP.

BMC Med Res Methodol. 2019 Oct 15;19(1):191. doi: 10.1186/s12874-019-0839-0.

3.

Renal Cell Carcinoma Follow-Up - Is it Time to Abandon Ultrasound?

Quinlan M, Wei G, Davis N, Poyet C, Perera M, Bolton D, Lawrentschuk N.

Curr Urol. 2019 Sep;13(1):19-24. doi: 10.1159/000499299. Epub 2019 Sep 10.

4.

Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.

Voskuilen CS, Oo HZ, Genitsch V, Smit LA, Vidal A, Meneses M, Necchi A, Colecchia M, Xylinas E, Fontugne J, Sibony M, Rouprêt M, Lenfant L, Côté JF, Buser L, Saba K, Furrer MA, van der Heijden MS, Daugaard M, Black PC, van Rhijn BWG, Hendricksen K, Poyet C, Seiler R.

Am J Surg Pathol. 2019 Dec;43(12):1600-1610. doi: 10.1097/PAS.0000000000001371.

PMID:
31524642
5.

High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.

Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser CD, Schmid MB, Rutishauser D, Ljubicic J, Christiansen A, Fritz C, Rupp NJ, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild PJ, Aebersold R, Guo T.

Mol Oncol. 2019 Nov;13(11):2305-2328. doi: 10.1002/1878-0261.12570. Epub 2019 Sep 18.

6.

Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins.

Shao W, Guo T, Toussaint NC, Xue P, Wagner U, Li L, Charmpi K, Zhu Y, Wu J, Buljan M, Sun R, Rutishauser D, Hermanns T, Fankhauser CD, Poyet C, Ljubicic J, Rupp N, Rüschoff JH, Zhong Q, Beyer A, Ji J, Collins BC, Liu Y, Rätsch G, Wild PJ, Aebersold R.

Nat Commun. 2019 Jun 7;10(1):2524. doi: 10.1038/s41467-019-10513-5.

7.

Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorship.

Wettstein MS, Pazhepurackel C, Neumann AS, Woon DTS, Herrera-Caceres JO, Kozomara M, Poyet C, Sulser T, Kulkarni GS, Hermanns T.

World J Urol. 2019 May 13. doi: 10.1007/s00345-019-02799-3. [Epub ahead of print]

PMID:
31087122
8.

Erratum: Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.

Fankhauser CD, Hermanns T, Lieger L, Diethelm O, Umbehr M, Luginbühl T, Sulser T, Müntener M, Poyet C.

Clin Kidney J. 2018 Apr 18;12(2):309-310. doi: 10.1093/ckj/sfy030. eCollection 2019 Apr.

9.

Pure Bipolar Plasma Vaporization of the Prostate: Results from a Prospective 3D Ultrasound Volumetry Study with Clinical Outcome After 3 Years.

Hermanns T, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Keller EX, Eberli D, Kozomara M, Sulser T, Poyet C, Kranzbühler B.

J Endourol. 2019 Feb;33(2):107-112. doi: 10.1089/end.2018.0700. Epub 2019 Feb 1.

PMID:
30612441
10.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.

Eur Urol Focus. 2018 Dec 14. pii: S2405-4569(18)30382-1. doi: 10.1016/j.euf.2018.12.002. [Epub ahead of print]

PMID:
30559065
11.

Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.

Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezavi A, Kaufmann B, Fankhauser CD, Wild P, Sulser T, Hermanns T, Eberli D, Poyet C.

World J Urol. 2019 Sep;37(9):1837-1844. doi: 10.1007/s00345-018-2578-y. Epub 2018 Dec 5.

PMID:
30519744
12.

Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.

Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U.

Int J Cancer. 2019 Apr 1;144(7):1676-1684. doi: 10.1002/ijc.31935. Epub 2018 Dec 30.

13.

Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers.

Guo T, Li L, Zhong Q, Rupp NJ, Charmpi K, Wong CE, Wagner U, Rueschoff JH, Jochum W, Fankhauser CD, Saba K, Poyet C, Wild PJ, Aebersold R, Beyer A.

Life Sci Alliance. 2018 May 29;1(2). pii: e201800042. doi: 10.26508/lsa.201800042.

14.

Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.

Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, Kaufmann PA, Hermanns T, Burger IA.

World J Urol. 2019 Mar;37(3):457-467. doi: 10.1007/s00345-018-2408-2. Epub 2018 Jul 20. Review.

PMID:
30030659
15.

Correction to: Prevalence of hypertension and diabetes after exposure to extracorporeal shock-wave lithotripsy in patients with renal calculi: a retrospective non-randomized data analysis.

Fankhauser CD, Mohebbi N, Grogg J, Holenstein A, Zhong Q, Hermanns T, Sulser T, Steurer J, Poyet C.

Int Urol Nephrol. 2018 Sep;50(9):1631. doi: 10.1007/s11255-018-1932-8.

16.

Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.

Fankhauser CD, Hermanns T, Lieger L, Diethelm O, Umbehr M, Luginbühl T, Sulser T, Müntener M, Poyet C.

Clin Kidney J. 2018 Jun;11(3):364-369. doi: 10.1093/ckj/sfx151. Epub 2018 Jan 25. Erratum in: Clin Kidney J. 2018 Apr 18;12(2):309-310.

17.

Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180 W GreenLight XPS laser?

Hermanns T, Grossmann NC, Wettstein MS, Keller EX, Fankhauser CD, Gross O, Kranzbühler B, Lüscher M, Meier AH, Sulser T, Poyet C.

World J Urol. 2019 Jan;37(1):181-187. doi: 10.1007/s00345-018-2377-5. Epub 2018 Jun 19.

PMID:
29923013
18.

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ.

Eur Urol. 2018 Aug;74(2):197-203. doi: 10.1016/j.eururo.2018.05.003. Epub 2018 May 16.

19.

Three-Dimensional Texture Analysis with Machine Learning Provides Incremental Predictive Information for Successful Shock Wave Lithotripsy in Patients with Kidney Stones.

Mannil M, von Spiczak J, Hermanns T, Poyet C, Alkadhi H, Fankhauser CD.

J Urol. 2018 Oct;200(4):829-836. doi: 10.1016/j.juro.2018.04.059. Epub 2018 Apr 17.

PMID:
29673945
20.

Author Correction: Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.

Sci Rep. 2018 Apr 11;8(1):6051. doi: 10.1038/s41598-018-23158-z.

21.

Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.

Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ.

Oncotarget. 2017 Dec 4;9(12):10284-10293. doi: 10.18632/oncotarget.22888. eCollection 2018 Feb 13.

22.

Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.

von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, Shariat SF, Xylinas E, Roghmann F; Young Academic Urologists′ Working Group on Urothelial Cancer of the European Association of Urology.

Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3.

PMID:
29506940
23.

Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Araúzo-Bravo MJ, Santourlidis S.

Sci Rep. 2018 Feb 22;8(1):3477. doi: 10.1038/s41598-018-21932-7. Erratum in: Sci Rep. 2018 Apr 11;8(1):6051.

24.

Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.

Roudnicky F, Yoon SY, Poghosyan S, Schwager S, Poyet C, Vella G, Bachmann SB, Karaman S, Shin JW, Otto VI, Detmar M.

Oncogene. 2018 May;37(19):2573-2585. doi: 10.1038/s41388-018-0129-z. Epub 2018 Feb 22.

25.

The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.

Umbehr MH, Bachmann LM, Poyet C, Hammerer P, Steurer J, Puhan MA, Frei A.

Health Qual Life Outcomes. 2018 Feb 20;16(1):36. doi: 10.1186/s12955-018-0859-1.

26.

Miniaturised percutaneous nephrolithotomy versus flexible ureteropyeloscopy: a systematic review and meta-analysis comparing clinical efficacy and safety profile.

Davis NF, Quinlan MR, Poyet C, Lawrentschuk N, Bolton DM, Webb D, Jack GS.

World J Urol. 2018 Jul;36(7):1127-1138. doi: 10.1007/s00345-018-2230-x. Epub 2018 Feb 16.

PMID:
29450733
27.

Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.

Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.

Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.

PMID:
28781111
28.

Prevalence and causes of abnormal PSA recovery.

Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild PJ, von Eckardstein A, Poyet C.

Clin Chem Lab Med. 2018 Jan 26;56(2):341-349. doi: 10.1515/cclm-2017-0246.

29.

The Next Generation of Prostate Cancer Risk Calculators.

Hermanns T, Poyet C.

Eur Urol. 2017 Dec;72(6):897-898. doi: 10.1016/j.eururo.2017.05.006. Epub 2017 May 15. No abstract available.

PMID:
28522179
30.

Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.

Mortezavi A, Salemi S, Rupp NJ, Rüschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D.

Oncotarget. 2017 May 9;8(19):31765-31774. doi: 10.18632/oncotarget.15986.

31.

Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.

Poyet C, Thomas L, Benoit TM, Delmo DA, Luberto L, Banzola I, Günthart MS, Sais G, Eberli D, Sulser T, Provenzano M.

Oncotarget. 2017 Mar 28;8(13):21871-21883. doi: 10.18632/oncotarget.15669.

32.

High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.

Roudnicky F, Dieterich LC, Poyet C, Buser L, Wild P, Tang D, Camenzind P, Ho CH, Otto VI, Detmar M.

J Pathol. 2017 Jun;242(2):193-205. doi: 10.1002/path.4892. Epub 2017 May 3.

33.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

34.

Detecting circulating tumor DNA in renal cancer: An open challenge.

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M.

Exp Mol Pathol. 2017 Apr;102(2):255-261. doi: 10.1016/j.yexmp.2017.02.009. Epub 2017 Feb 23.

PMID:
28214514
35.

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C.

Prostate. 2017 Apr;77(5):549-556. doi: 10.1002/pros.23296. Epub 2017 Jan 17.

36.

Prostate cancer risk calculators: still much work ahead.

Poyet C, Hermanns T.

BJU Int. 2016 Nov;118(5):670-671. doi: 10.1111/bju.13497. No abstract available.

37.

External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.

Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T, Vickers AJ, Hermanns T.

J Urol. 2016 Nov;196(5):1402-1407. doi: 10.1016/j.juro.2016.05.081. Epub 2016 May 14.

38.

Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry.

Kranzbühler B, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Hefermehl LJ, Zimmermann M, Müller A, Eberli D, Sulser T, Poyet C, Hermanns T.

World J Urol. 2017 Mar;35(3):429-435. doi: 10.1007/s00345-016-1876-5. Epub 2016 Jun 23.

39.

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M.

Cancer Cell. 2016 Jun 13;29(6):846-858. doi: 10.1016/j.ccell.2016.04.012. Epub 2016 May 26.

40.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

41.

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Müntener M, Wild PJ.

J Pathol Inform. 2016 Jan 29;7:3. doi: 10.4103/2153-3539.175376. eCollection 2016.

42.

[Male Urinary Incontinence--a Taboo Issue].

Kozomara-Hocke M, Hermanns T, Poyet C.

Praxis (Bern 1994). 2016 Mar 2;105(5):269-77. doi: 10.1024/1661-8157/a002297. Review. German.

43.

Clinical impact of prostate biopsy undergrading in an academic and community setting.

Mortezavi A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D.

World J Urol. 2016 Oct;34(10):1481-90. doi: 10.1007/s00345-016-1788-4. Epub 2016 Mar 1.

44.

IDLN-MSP: Idiolocal normalization of real-time methylation-specific PCR for genetic imbalanced DNA specimens.

Santourlidis S, Ghanjati F, Beermann A, Hermanns T, Poyet C.

Biotechniques. 2016 Feb 1;60(2):84-7. doi: 10.2144/000114379. eCollection 2016 Feb.

45.

Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.

Wettstein MS, Poyet C, Grossmann NC, Fankhauser CD, Keller EX, Kozomara M, Meyer S, Sulser T, Müller A, Hermanns T.

World J Urol. 2016 Sep;34(9):1261-7. doi: 10.1007/s00345-016-1766-x. Epub 2016 Jan 16.

PMID:
26780733
46.

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.

Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ.

Oncol Lett. 2015 Nov;10(5):2753-2760. Epub 2015 Sep 9.

47.

Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years.

Mortezavi A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, Hermanns T.

Clin Genitourin Cancer. 2016 Aug;14(4):290-7. doi: 10.1016/j.clgc.2015.11.006. Epub 2015 Nov 17.

PMID:
26710661
48.

Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer.

Umbehr MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, Müntener M.

Urol Int. 2016;96(3):309-14. doi: 10.1159/000441733. Epub 2015 Dec 16.

49.

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C.

Dis Markers. 2015;2015:785461. doi: 10.1155/2015/785461. Epub 2015 Oct 12.

50.

Predictive value of low tube voltage and dual-energy CT for successful shock wave lithotripsy: an in vitro study.

Largo R, Stolzmann P, Fankhauser CD, Poyet C, Wolfsgruber P, Sulser T, Alkadhi H, Winklhofer S.

Urolithiasis. 2016 Jun;44(3):271-6. doi: 10.1007/s00240-015-0824-y. Epub 2015 Sep 21.

PMID:
26391614

Supplemental Content

Support Center